Erin Colgan - Feb 15, 2022 Form 4 Insider Report for Sensei Biotherapeutics, Inc. (SNSE)

Role: Chief Financial Officer
Signature: /s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol: SNSE
Transactions as of: Feb 15, 2022
Transactions value $: $0
Form type: 4
Date filed: 2/17/2022, 05:21 PM
Next filing: Mar 29, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SNSE	Common Stock	Award	$0	+21K	+3061.22%	$0.00	21.7K	Feb 15, 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SNSE	Stock Option (Right to Buy)	Award	$0	+62K		$0.00	62K	Feb 15, 2022	Common Stock	62K	$4.30	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in four equal annual installments on each of February 15, 2023, February 15, 2024, February 15, 2025 and February 15, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such date.
F2	Includes 686 shares acquired by the Reporting Person pursuant to the Issuer's Employee Stock Purchase Plan.
F3	The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2023; and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.